2023
Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial.
Zisook S, Moutier C, Rush A, Johnson G, Tal I, Chen P, Davis L, Hicks P, Wilcox J, Planeta B, Lauro K, Scrymgeour A, Kasckow J, Mohamed S. Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial. Psychological Medicine 2023, 54: 1172-1183. PMID: 37859623, DOI: 10.1017/s0033291723003008.Peer-Reviewed Original ResearchMajor depressive disorderNext-step treatmentsLifetime suicidal ideationSuicidal ideationSuicide riskLower positive mental healthPrevalence of SISevere depressive episodeAcute treatment periodCurrent MDD episodeBaseline suicidal ideationMore childhood adversitiesSuicide prevention interventionsRisk of SICurrent suicidal ideationAntidepressant treatmentMost patientsInitial medicationMDD episodeMedication treatmentDepressive episodeDepressive disorderTreatment periodDepression trialsPrevention interventionsFactors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report
Hicks P, Sevilimedu V, Johnson G, Tal I, Chen P, Davis L, Vertrees J, Zisook S, Mohamed S. Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report. Psychiatric Research And Clinical Practice 2023, 5: 131-143. PMID: 38077276, PMCID: PMC10698706, DOI: 10.1176/appi.prcp.20230017.Peer-Reviewed Original ResearchGroup-based trajectory modelingBaseline depressionEarly improvementSwitching treatmentSingle-blind trialHigher baseline depressionDepression symptom changeAdditional exploratory analysesAssociation of treatmentMajor depressive disorderLogistic regression analysisDepression Outcomes studyDemographic factorsMultinomial logistic regression analysisSpecific depression symptomsExploratory analysisProbability of responseAntidepressant trialsSeverity scoreDepressive disorderTrial reportsOutcome studiesBaseline anxietyPrimary analysisTreatment interventions
2022
Childhood adversity and adulthood major depressive disorder
Zisook S, Planeta B, Hicks PB, Chen P, Davis LL, Villarreal G, Sapra M, Johnson GR, Mohamed S. Childhood adversity and adulthood major depressive disorder. General Hospital Psychiatry 2022, 76: 36-44. PMID: 35366613, DOI: 10.1016/j.genhosppsych.2022.03.008.Peer-Reviewed Original ResearchConceptsMajor depressive disorderChildhood adversityDepressive disorderSuicidal ideationLower remission rateLower depression severityDepression Outcomes studyMore lifetime episodesGOV IDENTIFIERRemission rateClinical featuresClinical outcomesSevere depressionTreatment strategiesLifetime episodesOutcome studiesDepression severitySwitching treatmentYounger ageSecondary analysisComorbid PTSDChildhood maltreatmentWorse qualitySpecific typesDisordersThe Impact of Mental Health Intensive Case Management on Functioning and Clinical Outcomes of Older Black and White Veterans With Serious Mental Illness
Browne J, Mohamed S. The Impact of Mental Health Intensive Case Management on Functioning and Clinical Outcomes of Older Black and White Veterans With Serious Mental Illness. American Journal Of Geriatric Psychiatry 2022, 30: 1183-1194. PMID: 35365385, DOI: 10.1016/j.jagp.2022.02.009.Peer-Reviewed Original ResearchConceptsSerious mental illnessIntensive case managementAnxiety/depressionClinical outcomesWhite veteransBlack veteransUse disordersMental illnessMental health recovery programsCase managementNational program evaluation dataDrug use disordersVeterans Health Administration programHigh-intensity servicesAlcohol use disorderSubstance use treatmentWhite older adultsGreater improvementService deliveryMedication managementBaseline differencesOutcome measuresSociodemographic factorsEqual-access settingSecondary analysis
2021
Evaluation of disparities in impact of mental health intensive case management on 6-month symptoms, functioning, and quality of life between black and white veterans diagnosed with schizophrenia
Browne J, Mohamed S. Evaluation of disparities in impact of mental health intensive case management on 6-month symptoms, functioning, and quality of life between black and white veterans diagnosed with schizophrenia. Schizophrenia Research 2021, 253: 68-74. PMID: 34247886, DOI: 10.1016/j.schres.2021.07.002.Peer-Reviewed Original ResearchConceptsEqual-access health care systemVeterans Health AdministrationWhite veteransHealth care systemClinical characteristicsClinical historySystem involvementMental health recovery programsCare systemService delivery differencesNational program evaluation dataSix-month changesEvaluation of disparitiesIntensive case managementQuality of lifeSubstantial health disparitiesMajority of outcomesJustice system involvementBaseline characteristicsClinical outcomesClinic settingService useSociodemographic factorsHealth AdministrationHealth disparitiesRates and Correlates of Suicidality in VA Intensive Case Management Programs
Mohamed S. Rates and Correlates of Suicidality in VA Intensive Case Management Programs. Community Mental Health Journal 2021, 58: 356-365. PMID: 33948867, DOI: 10.1007/s10597-021-00831-8.Peer-Reviewed Original ResearchConceptsIntensive case management servicesLogistic regression analysisCorrelates of suicidalityCase management servicesProgram entryMultivariable logistic regression analysisSuicidal behaviorIntensive case management programRates of suicidalityQuality of lifeCase management programRegression analysisChi-square testNational program evaluationClinical characteristicsBrief Symptom InventoryIndependent correlatesSubjective symptomsCrisis intervention servicesGreater receiptSquare testSymptom InventoryAdmissionSuicidalityIntervention services
2020
Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report
Zisook S, Johnson G, Hicks P, Chen P, Beresford T, Michalets J, Rao S, Thase M, Wilcox J, Sevilimedu V, Mohamed S. Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report. Depression And Anxiety 2020, 38: 185-195. PMID: 33225492, DOI: 10.1002/da.23114.Peer-Reviewed Original ResearchConceptsDepressive symptom severityContinuation treatmentBupropion SRTreatment outcomesTreatment-resistant major depressive disorderSymptom severitySignificant differential treatment effectsContinuation treatment phaseAcute-phase treatmentAbnormal laboratory valuesLower relapse rateMajor depressive disorderQuality of lifeLess anxietyDifferential treatment effectsMore somnolenceDry mouthRelapse rateExtrapyramidal effectsFull remissionWeek 12Continuation phaseTreatment attemptsDepressive disorderLaboratory valuesStages of major depressive disorder and behavioral multi-morbidities: Findings from nationally representative epidemiologic study
Rhee TG, Mohamed S, Rosenheck RA. Stages of major depressive disorder and behavioral multi-morbidities: Findings from nationally representative epidemiologic study. Journal Of Affective Disorders 2020, 278: 443-452. PMID: 33010569, DOI: 10.1016/j.jad.2020.09.081.Peer-Reviewed Original ResearchConceptsChronic major depressive disorderMajor depressive disorderNew-onset major depressive disorderOnset major depressive disorderBorderline personality disorderDepressive disorderUse disordersRepresentative cross-sectional surveyRepresentative epidemiologic studyPersonality disorderMore psychiatric disordersSubstance use disordersAlcohol use disorderNational Epidemiologic SurveyRelated Conditions-IIICross-sectional surveyDSM-5 diagnostic criteriaMultivariable analysisGroup of adultsEpidemiologic studiesUS adultsDiagnostic criteriaPsychiatric disordersEpidemiologic SurveyMDD historyImpact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Mohamed S, Johnson GR, Sevilimedu V, Rao SD, Hicks PB, Chen P, Lauro K, Jurjus G, Pilkinton P, Davis L, Wilcox JA, Iranmanesh A, Sapra M, Aslam M, Michalets J, Thase M, Zisook S. Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32603560, DOI: 10.4088/jcp.19m13038.Peer-Reviewed Original ResearchConceptsConcurrent posttraumatic stress disorderMajor depressive disorderPosttraumatic stress disorderDepressive disorderVeterans Health Administration medical centersNonpsychotic major depressive disorderStress disorderMini International Neuropsychiatric InterviewAdequate antidepressant treatmentPoor overall outcomeDepressive Symptomatology-Clinician RatedSevere depressive symptomsAntipsychotic augmentationInitial remissionAntidepressant treatmentSuboptimal responseAntipsychotic aripiprazoleCurrent antidepressantsAntidepressant trialsQuick InventoryNeuropsychiatric InterviewClinical trialsMedical CenterRemissionDepressive symptoms
2019
Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST‐D Trial Report
Hicks P, Sevilimedu V, Johnson G, Tal I, Chen P, Davis L, Vertrees J, Mohamed S, Zisook S. Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST‐D Trial Report. Psychiatric Research And Clinical Practice 2019, 1: 58-67. PMID: 36101874, PMCID: PMC9176018, DOI: 10.1176/appi.prcp.20190003.Peer-Reviewed Original ResearchNegative predictive valuePositive predictive valueEarly improvementWeek 2Antidepressant therapyAntidepressant treatmentPredictive valueSingle-blind trialDepressive Symptomatology-Clinician RatedMajor depressive disorderDepression Outcomes studyWeek 12Medication interventionsQuick InventoryDepressive disorderWeek 6Trial reportsOutcome studiesTreatment groupsDegree of improvementSwitching treatmentClinical decisionSecondary analysisRemissionMinimal improvementGeneral Predictors and Moderators of Depression Remission: A VAST-D Report
Zisook S, Johnson GR, Tal I, Hicks P, Chen P, Davis L, Thase M, Zhao Y, Vertrees J, Mohamed S. General Predictors and Moderators of Depression Remission: A VAST-D Report. American Journal Of Psychiatry 2019, 176: 348-357. PMID: 30947531, DOI: 10.1176/appi.ajp.2018.18091079.Peer-Reviewed Original ResearchMeSH KeywordsAdultAdverse Childhood ExperiencesAgedAged, 80 and overAntidepressive AgentsAripiprazoleBupropionDepressive Disorder, MajorDrug SubstitutionDrug Therapy, CombinationEmploymentFemaleGriefHumansLife TablesMaleMiddle AgedPrognosisQuality of LifeRemission InductionSeverity of Illness IndexSingle-Blind MethodUnited StatesUnited States Department of Veterans AffairsYoung AdultConceptsNext-step treatmentsRelease bupropionVeterans Health Administration patientsPatients' baseline featuresSingle-blind trialMajor depressive disorderDepression Outcomes studyComplicated grief symptomsAntidepressant treatmentBaseline characteristicsInitial treatmentDepression remissionDepressive disorderRemissionOutcome studiesTreatment selectionTreatment groupsHypomanic symptomsSwitching treatmentClinical imperativePositive mental healthChildhood adversityPatientsMental healthSpecific augmentation
2018
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.
Yoon J, Zisook S, Park A, Johnson GR, Scrymgeour A, Mohamed S. Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2018, 80 PMID: 30695291, DOI: 10.4088/jcp.18m12294.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive Agents, Second-GenerationAripiprazoleBupropionCost-Benefit AnalysisDepressionDepressive Disorder, MajorDrug SubstitutionDrug SynergismDrug Therapy, CombinationFemaleHumansMaleMiddle AgedOutcome Assessment, Health CareRemission InductionUnited StatesUnited States Department of Veterans AffairsVeteransConceptsIncremental cost-effectiveness ratioStandard antidepressant therapyBupropion augmentationAripiprazole augmentationAntidepressant therapyClinical trialsVeterans Affairs Medical CenterDepression Outcomes trialMental health care costsRate of remissionRandomized clinical trialsHealth care sector perspectiveICD-9 codesTreatment of depressionCost-effectiveness ratioHealth care costsCost-effective relativeCost-effectiveness analysisOutcome trialsMean ageQuick InventoryDepression diagnosisTreatment strategiesRemissionMedical Center
2017
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial
Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao S, Pilkinton P, Wilcox J, Iranmanesh A, Sapra M, Jurjus G, Michalets J, Aslam M, Beresford T, Anderson K, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D’Souza D, Larson G, Anderson W, Klatt M, Fareed A, Thompson S, Carrera C, Williams S, Juergens T, Albers L, Nasdahl C, Villarreal G, Winston J, Nogues C, Connolly K, Tapp A, Jones K, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda A, Niculescu A, Fischer B, Loreck D, Rosenlicht N, Lieske S, Finkel M, Little J. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017, 318: 132-145. PMID: 28697253, PMCID: PMC5817471, DOI: 10.1001/jama.2017.8036.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAcute treatment phaseDepressive disorderSwitch groupAdverse effectsTreatment phaseUS Veterans Health Administration medical centersVeterans Health Administration medical centersNonpsychotic major depressive disorderWeeks of treatmentEffects of antidepressantsLikelihood of remissionSignificant treatment differencesBupropion monotherapyRandomized patientsRemission rateBupropion groupSecondary outcomesPrimary outcomeAtypical antipsychoticsDifferent antidepressantsFirst antidepressantClinical trialsCurrent treatmentMedical Center
2016
Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income
Rosenheck R, Mueser KT, Sint K, Lin H, Lynde DW, Glynn SM, Robinson DG, Schooler NR, Marcy P, Mohamed S, Kane JM. Supported employment and education in comprehensive, integrated care for first episode psychosis: Effects on work, school, and disability income. Schizophrenia Research 2016, 182: 120-128. PMID: 27667369, DOI: 10.1016/j.schres.2016.09.024.Peer-Reviewed Original ResearchConceptsCommunity carePublic support incomeFirst episode psychosis programUsual community careGeneral estimation equation modelsFirst-episode psychosisEstimation equation modelsPsychosis programPublic support paymentsEpisode psychosisTreatment clinicsDays of participationTreatment approachesFEP participantsIntegrated careStudy participantsTreatment programEvidence effectivenessMonthly assessmentsGroup differencesIndividual PlacementDisability incomeGreater improvementGreater increaseCareInitiation of pharmacotherapy for post-traumatic stress disorder among veterans from Iraq and Afghanistan: a dimensional, symptom cluster approach
Harpaz-Rotem I, Rosenheck R, Mohamed S, Pietrzak R, Hoff R. Initiation of pharmacotherapy for post-traumatic stress disorder among veterans from Iraq and Afghanistan: a dimensional, symptom cluster approach. BJPsych Open 2016, 2: 286-293. PMID: 27703791, PMCID: PMC5016711, DOI: 10.1192/bjpo.bp.115.002451.Peer-Reviewed Original ResearchPost-traumatic stress disorderAnxiolytics/sedatives/hypnoticsPTSD diagnosisUS Veterans Health AdministrationPhenotypic presentationInitiation of pharmacotherapyPrescription of antidepressantsSedative/hypnoticsVeterans Health AdministrationHeterogeneous phenotypic presentationsMilitary-related post-traumatic stress disorderHypnotic prescriptionsMedication classesPrescribing patternsFirst prescriptionMultivariable analysisPharmacological treatmentClinical guidelinesInitial episodeUS veteransPTSD symptom clustersRe-experiencing symptomsSleep difficultiesHealth AdministrationSymptom clustersComparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China
Zhou Y, Rosenheck R, Mohamed S, Ou Y, Ning Y, He H. Comparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China. BMC Psychiatry 2016, 16: 283. PMID: 27515535, PMCID: PMC4980784, DOI: 10.1186/s12888-016-0962-y.Peer-Reviewed Original ResearchConceptsFamily burdenBipolar disorderPsychiatric hospitalDifference of burdenWeeks of patientsMethodsTwo hundred fortyCross-sectional studyFamilies of patientsAcute psychiatric hospitalLarge psychiatric hospitalBipolar disorder patientsQuality of lifeComparison of burdenClinical featuresAcute patientsPredictive factorsCaregiver burdenHundred fortyDisorder patientsSchizophrenic patientsBipolar patientsPatientsSchizophrenia patientsSuicidal riskCaregivers' perceptionsCharacteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report
Zisook S, Tal I, Weingart K, Hicks P, Davis LL, Chen P, Yoon J, Johnson GR, Vertrees JE, Rao S, Pilkinton PD, Wilcox JA, Sapra M, Iranmanesh A, Huang GD, Mohamed S. Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report. Journal Of Affective Disorders 2016, 206: 232-240. PMID: 27479536, DOI: 10.1016/j.jad.2016.07.023.Peer-Reviewed Original ResearchConceptsMajor depressive disorderClinical featuresDepressive disorderNonpsychotic major depressive disorderInitial standard treatmentNon-veteran samplesU.S. veteran patientsCharacteristics of patientsSample of veteransRecent suicidal ideationPublic health imperativeLasting treatmentMDD treatmentVeteran patientsClinical onsetPsychiatric comorbidityAntidepressant trialsStandard treatmentClinical trialsDepression subtypesRecurrent depressionIndividual patientsSpecific treatmentPatientsSuicidal ideationComparison of Intensive Case Management for Psychotic and Nonpsychotic Patients
Mohamed S. Comparison of Intensive Case Management for Psychotic and Nonpsychotic Patients. Psychological Services 2016, 13: 10-19. PMID: 26168139, DOI: 10.1037/ser0000041.Peer-Reviewed Original ResearchConceptsAssertive community treatmentPsychotic symptomsAnalysis of covariancePsychotic disordersIntensive case management programIntensive case management servicesSevere psychotic symptomsIntensive case managementCommunity-based careCase management programCase management servicesInpatient bed availabilityCommunity-based service programsBaseline characteristicsMedication complianceNonpsychotic patientsNonpsychotic disordersOutcome dataPsychotic diagnosesHospital useCommunity treatmentSuch symptomsBed availabilitySymptomsCase management
2015
The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations
Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, Zisook S. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Research 2015, 229: 760-770. PMID: 26279130, DOI: 10.1016/j.psychres.2015.08.005.Peer-Reviewed Original ResearchRandomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia
Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2015, 203: 486-492. PMID: 26075840, DOI: 10.1097/nmd.0000000000000317.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcoholismAntipsychotic AgentsBenzodiazepinesChronic DiseaseComorbidityCross-Sectional StudiesDibenzothiazepinesDouble-Blind MethodFemaleHumansIllicit DrugsMaleMiddle AgedOlanzapinePerphenazinePiperazinesPsychiatric Status Rating ScalesQuetiapine FumarateRisperidoneSchizophreniaSchizophrenic PsychologySmokingSmoking PreventionSubstance-Related DisordersThiazolesYoung AdultConceptsSecond-generation antipsychotic drugsAntipsychotic drugsFirst-generation antipsychoticsSecond-generation antipsychoticsIntervention Effectiveness (CATIE) studySecondary outcome dataClinical Antipsychotic TrialsFirst-generation drugsSubstance use outcomesCigarette smokingSchizophrenia trialsChronic schizophreniaAntipsychotic TrialsOutcome dataNicotine useDrug useSecondary analysisPast weekAntipsychoticsEffectiveness studiesPatientsSubstance useUse outcomesTrialsDrugs